Abstract
REPORT DESCRIPTION
Autoimmune disorders result from an overactive immune response of a body
working against its own cells. The disease is broadly classified into two
types: systemic autoimmune diseases, which affect several organs of the body;
and localized autoimmune diseases, which affect only one organ. Around 80
autoimmune diseases are recognized under these two categories. The disease
affected over 300 million people across the globe in 2009. No defined reasons
have been discovered to date for the occurrence of the disorder. Women are
more prone to autoimmune diseases, constituting 70%-75% of all autoimmune
patients.
The overall market for the treatment of autoimmune disorders is analyzed into
the submarkets for applications, products, services, and technologies. The
global market for autoimmune disease treatments is estimated to be at $37.84
billion in 2009, and is growing at a CAGR of 12.7% from 2009 to 2014 to reach
an estimated $68.81 billion in 2014. The effects of the global meltdown are
given careful consideration when forecasting the market.
The application market is further classified into the treatment markets for
systemic autoimmune diseases and localized autoimmune diseases. The
applications market is dominated mostly by rheumatoid arthritis under the
systemic disease segment, while multiple sclerosis is the major application
market under the localized disease segment. These two disorders account for
75% of the total applications market. The other major diseases analysed under
the application market are psoriasis, lupus, type I diabetes, inflammatory
bowel disease, and thyroid disorders, which together account for 15%-20% of
the global applications market.
The product market is classified on the basis of the drugs, diagnostic
equipments, therapeutic and monitoring equipment. Drugs form the largest
segment of the products market, with major drugs such as NSAID, DMARD,
biologic DMARD, Avonex, Rebif, Copaxone, Betaseron, and 5-ASA. The services
market consists of consultation and diagnosis, therapy and monitoring, and
drug development. The wide and increasing prevalence of autoimmune diseases is
boosting the drugs market along with the therapy and monitoring market; along
with the fact that almost all autoimmune diseases are chronic and have no
permanent cure.
The drugs market is estimated to have a revenue of $24.38 billion in 2009, and
it is growing with a CAGR of 12.5% from 2009 to 2014. The total services
market with therapy and monitoring and drug development as the largest
contributor is estimated to be at $9.31 billion in 2009 and it is growing at a
CAGR of 14% from 2009 to 2014. Scope of the Report
The report provides market overviews and forecasts as well as market drivers
and restraints for the global autoimmune treatment market. In addition, it
profiles the top forty market players and their respective autoimmune
| 
View Cart
